TERMINATION AGREEMENT between CUREVAC AG and ELI LILLY AND COMPANYEli Lilly and Company • July 21st, 2020 • CureVac B.V. • Pharmaceutical preparations
CUREVAC REAL ESTATE GMBH, a German limited liability company, having a place of business at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany (CureVac AG and CureVac Real Estate GmbH jointly “CureVac”) and
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT between NEXTCURE, INC. and ELI LILLY AND COMPANYEli Lilly and Company • April 12th, 2019 • NextCure, Inc. • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) is effective as of November 2, 2018 (the “Effective Date”), and is entered into by and between:
RESEARCH COLLABORATION AND LICENSE AGREEMENTEli Lilly and Company • February 2nd, 2021 • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), effective as of the date this Agreement is duly executed by both Parties (the “Effective Date”), by and between ELI LILLY AND COMPANY, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”) and ABCELLERA BIOLOGICS INC., a corporation organized under the laws of British Columbia, Canada, with its principle business office located at 2215 Yukon St., Vancouver, BC V5Y 0A1, Canada (“AbCellera”). AbCellera and Lilly are each referred to individually as a “Party” and together as the “Parties”.
ELI LILLY AND COMPANY Medium-Term Notes Due More Than Nine Months from Date of Issue U.S. DISTRIBUTION AGREEMENTEli Lilly and Company • November 22nd, 1995 • Lilly Eli & Co • Pharmaceutical preparations • New York
